Hints and tips:
...” or “U-shaped”....
...From Market Watch: French pharmaceuticals major Sanofi-Aventis SA confirmed Wednesday it has struck a deal to buy U.S. peer Genzyme Corp....
...Sanofi-Aventis has continued aggressively to acquire others, including ultimately winning support for the takeover of US group Genzyme after raising its bid above $20bn....
...Sanofi-Aventis stepped up its pursuit of Genzyme on Sunday, outlining publicly its interest in a takeover deal as it inched closer to making a hostile offer for the US biotech company....
...The former ABB, Aventis and Hoechst boss was selected for his international experience and management skills....
...In pharmaceuticals, the government engineered the merger between Sanofi and Aventis to create a new champion rather than allow the Swiss Novartis to swallow it up....
...Total’s fourth-quarter adjusted net income – the number most watched by analysts which strips out gains from changes in the value of fuel inventories, one-off items and the value of Total’s stake in Sanofi-Aventis...
...A study by a British medical journal reported that a blood-thinning pill developed by the company worked better than Plavix, a rival drug made by Sanofi-Aventis....
...If growth in developed countries starts to look like a “U”, in emerging markets it already is a “V”....
...Then again, now that the Dutch group has flagged its interest in a takeover, Sanofi-Aventis and its rivals may come back with counter offers....
...Germans recall with bitterness the government intervention that ensured French control of the Franco-German pharmaceutical group Aventis, today known as Sanofi-Aventis....
...Bernstein saw Bristol-Myers Squibb, GlaxoSmithKline and Sanofi Aventis among potential buyers of the franchise....
...Swiss drugmaker Novartis gained 23.7 per cent to SFr59.50 while in France, Sanofi-Aventis climbed 17.2 per cent to €44.44. Germany’s BMW was boosted by an upgrade from Goldman Sachs....
...Hedge – Class B = 15% Short Credit Fund = 9% U.S....
...Shares in Bristol-Myers Squibb fell 3.3 per cent to $27.59 after reports of a break-down in the merger talks with Sanofi-Aventis ....
...Sanofi-Aventis climbed 2.5 per cent to €72.65 while Novartis added 1.1 per cent to €71.35....
...Sanofi-Aventis faces its own court battle over generic competition for its blood-thinning drug Plavix....
...Other gainers included Sanofi-Aventis, up 0.9 per cent at €69.35, and Serono, 0.9 per cent firmer at SFr859....
...Shares in Novo Nordisk retreated 1.5 per cent to DKr323.50, while Novartis fell back 1.1 per cent to SFr61.65, Sanofi-Aventis eased 1.6 per cent to €70.65 and Roche lost 1.1 per cent to SFr173.60....
...Sanofi-Aventis, the drugmaker, announced sales growth of 6.5 per cent in the second quarter, a little below expectations, knocking the shares 0.6 per cent to €70....
...It follows a bout of economic nationalism in France, where the government last year engineered the takeover of Aventis, the pharmaceuticals company, by rival Sanofi, and the bailout of engineering group...
...Sanofi-Aventis, the French drugs group, tumbled 5.4 per cent to €67.30 after it said a generic-drug maker had won a summary judgement in a US court over the patent covering Sanofi’s key Lovenox stroke treatment...
...Other stocks in the sector also stood firm, with Sanofi-Aventis up 0.3 per cent to €67 and Novartis 2.3 per cent higher at SFr57.25....
...The company, created through the acquisition of Aventis by Sanofi-Synthelabo, confirmed that pre-tax synergies from the merger would total €1.6bn by 2006. Sanofi shares rose 1.8 to €61.50....
...Pharmaceuticals were also back in the news, with Sanofi-Aventis falling 2.3 per cent to €62.80 following mixed results from a study of its experimental obesity drug, Acomplia....
International Edition